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Bordetella pertussis, the causative agent of whooping cough, was nearly eradicated upon the introduction of a 
vaccine in the 1920s. This whole cell vaccine was highly immunogenic and thus was replaced by an acellular 
vaccine in the mid-1990s. In recent decades, infection rates have risen dramatically in industrialized countries 
reaching a 60-year US high in 2012. Worldwide, B. pertussis remains a major cause of infant death, claiming 
approximately 195,000 lives annually. This appears partially due to shortcomings of the current vaccine, which 
confers short-term immunity and seems to prevent the symptoms of disease but not its spread.  
 
 The acellular vaccine varies between manufacturers, but consistently contains two important virulence factors, 
pertussis toxin (PTX) and filamentous hemagglutinin (FHA) and can additionally contain up to three adhesion 
factors. While this vaccine can mount neutralizing responses, the immunity it induces wanes over time. Current 
estimates have established the vaccine provides a decade of immunity and therapeutic strategies advise to 
boost often. This is especially detrimental to new parents who have become susceptible to the disease and 
have young infants who are too young to receive the vaccine.  
 
A possible route to enhance the vaccine is inclusion of additional antigens. The adenylate cyclase toxin (ACT), 
an essential colonization factor, is the leading candidate for inclusion in future vaccines. Yet, there is surprisingly 
little data detailing the mechanisms by which ACT confers protection or its appropriateness for manufacturing 
and formulation as a part of a multi-component vaccine. We have performed protein engineering on ACT to 
identify domains that are well-expressed, protective, and elicit neutralizing antibodies. We are currently using 
the original ACT and our engineered, more stable, and immunodominant variant in mouse immunization 
experiments to dissect ACT’s role in infection.  
 
Currently, our collaborators are working of including our recombinant RTX in the acellular vaccine in challenge 
models. Their work is showing promise in its inclusion.  In parallel, we seek to provide an immunotherapy to 
vulnerable infants who are too young to receive the vaccine. Providing neutralizing anti-ACT antibodies to infant 
mice prior to bacterial challenge initially proved ineffective when injected intraperitoneally. We hypothesize this 
as a mass transfer limitation in getting to the site of action, the respiratory tract. Therefore, we have developed a 
proof-of-principle system in evaluating several lung delivery models. When delivered to the lungs, protection 
provides several insights. First, successful protection implies an effective prophylaxis to high-risk infants. This 
could be especially powerful as we currently have an anti-PTX antibody in non-human primate trials that 
successfully alleviates symptoms of elevated white blood cell count, but it does not mitigate colonization. A 
cocktail with anti-PTX and anti-ACT antibodies could therefore provide a one-two punch at the site of 
colonization and a systemic therapeutic. Secondly, protection with anti-ACT antibodies suggests inclusion of this 
antigen into the vaccine will adequately provide a robust immune response.   
 
All in all, we have established the importance of an adenylate cyclase toxin, an essential colonization factor, in 
invoking immunity for Bordetella pertussis vaccine and passive immunization therapeutics. 
 
